+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Checkpoint Inhibitors"

Disease Analysis: Gastric Cancer - Product Thumbnail Image

Disease Analysis: Gastric Cancer

  • Report
  • June 2021
  • 88 Pages
  • Global
Disease Analysis: Bladder Cancer - Product Thumbnail Image

Disease Analysis: Bladder Cancer

  • Report
  • April 2021
  • 91 Pages
  • Global
Disease Analysis: Non-Small Cell Lung Cancer (NSCLC) - Product Thumbnail Image

Disease Analysis: Non-Small Cell Lung Cancer (NSCLC)

  • Report
  • April 2021
  • 191 Pages
  • Global
Disease Analysis: Head and Neck Cancer - Product Thumbnail Image

Disease Analysis: Head and Neck Cancer

  • Report
  • March 2021
  • 77 Pages
  • Global
Bladder Cancer Pricing, Reimbursement, and Access - Product Thumbnail Image

Bladder Cancer Pricing, Reimbursement, and Access

  • Report
  • September 2018
  • 79 Pages
  • Global
From
CD40 Ligand - Pipeline Review, H2 2019 - Product Thumbnail Image

CD40 Ligand - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 74 Pages
  • Global
From
Cancer Testis Antigen 1 - Pipeline Review, H2 2019 - Product Thumbnail Image

Cancer Testis Antigen 1 - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 76 Pages
  • Global
From
From
From
Bladder Cancer: Opportunity Analysis and Forecasts to 2028 - Product Thumbnail Image

Bladder Cancer: Opportunity Analysis and Forecasts to 2028

  • Report
  • February 2020
  • 131 Pages
  • Global
From
From
From
From
Loading Indicator

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more